Vascular Biogenics Ltd. | CIK:0001603207 | 3

  • Filed: 3/15/2018
  • Entity registrant name: Vascular Biogenics Ltd. (CIK: 0001603207)
  • Generator: Novaworks Software
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1603207/000149315218003377/0001493152-18-003377-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1603207/000149315218003377/vblt-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001603207
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory

      n. Research and development expenses

     

    Research expenses are charged to profit or loss as incurred. An intangible asset arising from development of the Company’s products is recognized if all of the following conditions are met:

     

      It is technically feasible to complete the intangible asset so that it will be available for use;
         
      Management intends to complete the intangible asset and use it or sell it;
         
      There is an ability to use or sell the intangible asset;
         
      It can be demonstrated how the intangible asset will generate probable future economic benefits;
         
      Adequate technical, financial and other resources to complete the development and to use or sell the intangible asset are available;
         
      Costs associated with the intangible asset during development can be measured reliably.

     

    Other development costs that do not meet the above criteria are recognized as expenses as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period.

     

    As of December 31, 2017, the Company has not yet capitalized any development costs.